Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk (original) (raw)

References

  1. Kyle, R.A. & Rajkumar, S.V. Multiple myeloma. N. Engl. J. Med. 351, 1860–1873 (2004).
    Article CAS PubMed Google Scholar
  2. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046–1060 (2011).
    Article CAS PubMed Google Scholar
  3. Broderick, P. et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat. Genet. 44, 58–61 (2012).
    Article CAS Google Scholar
  4. Weinhold, N. et al. The CCND1 G870A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat. Genet. 45, 522–525 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  5. Schmermund, A. et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk factors, evaluation of coronary calcium and lifestyle. Am. Heart J. 144, 212–218 (2002).
    Article PubMed Google Scholar
  6. Morgan, G.J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989–1999 (2010).
    Article CAS PubMed Google Scholar
  7. Power, C. & Elliott, J. Cohort profile: 1958 British birth cohort (National Child Development Study). Int. J. Epidemiol. 35, 34–41 (2006).
    Article PubMed Google Scholar
  8. Clayton, D.G. et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat. Genet. 37, 1243–1246 (2005).
    Article CAS PubMed Google Scholar
  9. Price, A.L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904–909 (2006).
    Article CAS PubMed Google Scholar
  10. Pettiti, D. Meta-analysis decision analysis and cost-effectivness analysis. Oxford University Press (1994).
  11. Houlston, R.S. et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat. Genet. 42, 973–977 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  12. Jones, A.M. et al. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 61, 248–254 (2012).
    Article CAS PubMed Google Scholar
  13. Skibola, C.F. et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat. Genet. 41, 873–875 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  14. Conde, L. et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat. Genet. 42, 661–664 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  15. Smedby, K.E. et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 7, e1001378 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  16. Enciso-Mora, V. et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat. Genet. 42, 1126–1130 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  17. Leslie, S., Donnelly, P. & McVean, G. A statistical method for predicting classical HLA alleles from SNP data. Am. J. Hum. Genet. 82, 48–56 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  18. Dilthey, A.T., Moutsianas, L., Leslie, S. & McVean, G. HLA*IMP—an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinformatics 27, 968–972 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  19. Gross, J.A. et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15, 289–302 (2001).
    Article CAS PubMed Google Scholar
  20. Liao, M. et al. Genome-wide association study identifies common variants at TNFRSF13B associated with IgG level in a healthy Chinese male population. Genes Immun. 13, 509–513 (2012).
    Article CAS PubMed Google Scholar
  21. Seshasayee, D. et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18, 279–288 (2003).
    Article CAS PubMed Google Scholar
  22. Moreaux, J. et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106, 1021–1030 (2005).
    Article CAS PubMed Google Scholar
  23. Yaccoby, S. et al. Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22, 406–413 (2008).
    Article CAS PubMed Google Scholar
  24. Gil, J., Bernard, D. & Peters, G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol. 24, 117–125 (2005).
    Article CAS PubMed Google Scholar
  25. Aguilo, F., Zhou, M.M. & Walsh, M.J. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res. 71, 5365–5369 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  26. Scott, C.L. et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc. Natl. Acad. Sci. USA 104, 5389–5394 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  27. Walker, B.A. et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108, 1733–1743 (2006).
    Article CAS PubMed Google Scholar
  28. Nica, A.C. et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 7, e1002003 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  29. Stranger, B.E. et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 8, e1002639 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  30. Dimas, A.S. et al. Common regulatory variation impacts gene expression in a cell type–dependent manner. Science 325, 1246–1250 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  31. Ernst, J. & Kellis, M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 28, 817–825 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  32. Dewald, G.W., Kyle, R.A., Hicks, G.A. & Greipp, P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66, 380–390 (1985).
    Article CAS PubMed Google Scholar
  33. Debes-Marun, C.S. et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17, 427–436 (2003).
    Article CAS PubMed Google Scholar
  34. Fonseca, R. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210–2221 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  35. Walker, B.A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56–e65 (2010).
    Article CAS PubMed Google Scholar
  36. Eisen, T., Matakidou, A. & Houlston, R. Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS). BMC Cancer 8, 244 (2008).
    Article PubMed PubMed Central Google Scholar
  37. Penegar, S. et al. National study of colorectal cancer genetics. Br. J. Cancer 97, 1305–1309 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  38. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
    CAS PubMed PubMed Central Google Scholar
  39. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
    Article PubMed Google Scholar
  40. Ioannidis, J.P., Ntzani, E.E. & Trikalinos, T.A. 'Racial' differences in genetic effects for complex diseases. Nat. Genet. 36, 1312–1318 (2004).
    Article CAS PubMed Google Scholar
  41. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  42. Altieri, A., Chen, B., Bermejo, J.L., Castro, F. & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer 42, 1661–1670 (2006).
    Article PubMed Google Scholar
  43. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007).
    Article CAS PubMed Google Scholar
  44. Myers, S., Bottolo, L., Freeman, C., McVean, G. & Donnelly, P. A fine-scale map of recombination rates and hotspots across the human genome. Science 310, 321–324 (2005).
    Article CAS PubMed Google Scholar
  45. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225–2229 (2002).
    Article CAS PubMed Google Scholar
  46. Chiecchio, L. et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20, 1610–1617 (2006).
    Article CAS PubMed Google Scholar
  47. Neben, K. et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95, 1150–1157 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  48. Stranger, B.E. et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 1, e78 (2005).
    Article PubMed PubMed Central Google Scholar
  49. Stranger, B.E. et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315, 848–853 (2007).
    Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

Leukaemia Lymphoma Research and Myeloma UK provided principal funding for this study in the UK. Additional funding was provided by Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the NHS through the Biological Research Centre of the National Institute for Health Research at the Royal Marsden Hospital NHS Trust. This study made use of genotyping data from the 1958 Birth Cohort. Genotyping data on controls were generated by the Wellcome Trust Sanger Institute. A full list of the investigators who contributed to the generation of the data is available at http://www.wtccc.org.uk. In Germany (Heidelberg), funding was provided to Dietmar-Hopp-Stiftung Walldorf, the University Hospital Heidelberg, Deutsche Krebshilfe and the Systems Medicine funding from the German Ministry of Education and Science. We are grateful to all investigators who contributed to the National Study of Colorectal Cancer Genetics (NSCCG) and the Genetic Lung Cancer Predisposition Study (GELCAPS), from which controls in the replication were drawn. The GWAS made use of genotyping data from the population-based HNR study. The HNR study is supported by the Heinz Nixdorf Foundation (Germany). Additionally, the study is funded by the German Ministry of Education and Science and the German Research Council (DFG; projects SI 236/8-1, SI236/9-1, ER 155/6-1 and DFG CRU 216). Funding was provided to L.E. by the Medical Faculty of the University Hospital of Essen (IFORES). The genotyping of the Illumina HumanOmni-1 Quad BeadChips of the HNR subjects was financed by DZNE, Bonn. We are extremely grateful to all investigators who contributed to the generation of this data set. The German replication controls were collected by P. Bugert, Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service of Baden-Württemberg-Hessen, Mannheim, Germany. We are grateful to all the patients and investigators at the individual centers for their participation. We also thank the staff of the Clinical Trials Research Unit University of Leeds and the National Cancer Research Institute Haematology Clinical Studies Group.

Author information

Author notes

  1. Daniel Chubb and Niels Weinhold: These authors contributed equally to this work.
  2. Gareth J Morgan, Kari Hemminki, Richard S Houlston and Hartmut Goldschmidt: These authors jointly directed this work.

Authors and Affiliations

  1. Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK
    Daniel Chubb, Peter Broderick, Jayaram Vijayakrishnan, Gabriele Migliorini, Sara E Dobbins, Amy Holroyd & Richard S Houlston
  2. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Niels Weinhold, Dirk Hose, Kai Neben, Elisabeth Dörner & Hartmut Goldschmidt
  3. German Cancer Research Center, Heidelberg, Germany
    Bowang Chen, Asta Försti & Kari Hemminki
  4. Department of Haemato-Oncology, Division of Pathology, Institute of Cancer Research, Surrey, UK
    David C Johnson, Brian A Walker, Faith E Davies & Gareth J Morgan
  5. Center for Primary Health Care Research, Lund University, Malmo, Sweden
    Asta Försti & Kari Hemminki
  6. National Centre of Tumour Diseases, Heidelberg, Germany
    Dirk Hose & Hartmut Goldschmidt
  7. Leeds Institute of Molecular Medicine, Section of Clinical Trials Research, University of Leeds, Leeds, UK
    Walter A Gregory
  8. Royal Victoria Infirmary, Newcastle upon Tyne, UK
    Graham H Jackson
  9. Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, UK
    Julie A Irving & James M Allan
  10. Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK
    Guy Pratt
  11. Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Chris Fegan
  12. Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK
    James A L Fenton
  13. Institute of Human Genetics, University of Bonn, Bonn, Germany
    Per Hoffmann, Markus M Nöthen & Thomas W Mühleisen
  14. Department of Genomics, University of Bonn, Bonn, Germany
    Per Hoffmann, Markus M Nöthen & Thomas W Mühleisen
  15. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
    Markus M Nöthen
  16. Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
    Lewin Eisele
  17. Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, UK
    Fiona M Ross
  18. Schön Klinik Starnberger See, Berg, Germany
    Christian Straka
  19. Department of Internal Medicine II, University of Würzburg, Würzburg, Germany
    Hermann Einsele
  20. Department of Internal Medicine III, University of Ulm, Ulm, Germany
    Christian Langer
  21. Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany
    Anna Jauch

Authors

  1. Daniel Chubb
  2. Niels Weinhold
  3. Peter Broderick
  4. Bowang Chen
  5. David C Johnson
  6. Asta Försti
  7. Jayaram Vijayakrishnan
  8. Gabriele Migliorini
  9. Sara E Dobbins
  10. Amy Holroyd
  11. Dirk Hose
  12. Brian A Walker
  13. Faith E Davies
  14. Walter A Gregory
  15. Graham H Jackson
  16. Julie A Irving
  17. Guy Pratt
  18. Chris Fegan
  19. James A L Fenton
  20. Kai Neben
  21. Per Hoffmann
  22. Markus M Nöthen
  23. Thomas W Mühleisen
  24. Lewin Eisele
  25. Fiona M Ross
  26. Christian Straka
  27. Hermann Einsele
  28. Christian Langer
  29. Elisabeth Dörner
  30. James M Allan
  31. Anna Jauch
  32. Gareth J Morgan
  33. Kari Hemminki
  34. Richard S Houlston
  35. Hartmut Goldschmidt

Contributions

R.S.H. and K.H. designed the study. R.S.H. and G.M. obtained financial support in the UK, and K.H. and H.G. obtained support in Germany. R.S.H. drafted the manuscript. D.C., B.C. and N.W. performed the principal statistical and bioinformatic analyses. S.E.D. and G.M. performed additional statistical and bioinformatic analyses. P.B. coordinated the UK laboratory analyses. J.V. and A.H. performed genotyping in the UK. D.C.J. managed and prepared Myeloma IX and Myeloma XI case study DNA samples. J.M.A. conceived of the Newcastle-based myeloma study (NMS). J.M.A. established the study and supervised data collation and sample management of the NMS. J.A.I., G.H.J., G.P., J.A.L.F. and C.F. developed protocols for the recruitment of individuals with myeloma and performed sample collection of cases within the NMS. H.G., D.H., K.N. and N.W. coordinated and managed the German DNA samples, and K.H. and A.F. coordinated the German genotyping. H.E., C.L. and C.S. ascertained and collected DSMM and Ulm case study samples, and C.L. prepared DNA samples. E.D. and N.W. performed genotyping of German replication cases and controls. B.A.W. performed UK expression analyses. F.M.R. performed UK and A.J. performed German FISH analyses. G.J.M., F.E.D., W.A.G., G.H.J. and J.A.I. performed ascertainment and collection of case study samples. P.H., T.W.M. and M.M.N. performed and coordinated the GWAS of German cases and controls. L.E. ascertained and managed the HNR sample. All authors contributed to the final paper.

Corresponding author

Correspondence toRichard S Houlston.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Source data

Rights and permissions

About this article

Cite this article

Chubb, D., Weinhold, N., Broderick, P. et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.Nat Genet 45, 1221–1225 (2013). https://doi.org/10.1038/ng.2733

Download citation